Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study. (PubMed, Diabetes Care) - Sep 22, 2026 - "Empagliflozin reduced cardiovascular events across sociodemographic and CVD subgroups compared with both DPP4is and GLP-1RAs, with higher absolute benefits observed in those with prevalent CVD."
Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus
|
|
Christina M Shay; Deborah J Wexler; Elisabetta Patorno; Hanseul Cho; Helen Tesfaye; Janinne Ortega-Montiel; Julie M Paik; Niklas Schmedt; Sara J Cromer
|